Overview
Epithelial tumors of the ovary encompass a spectrum of malignancies characterized by the uncontrolled growth of epithelial cells lining the ovary. These tumors can range from benign to highly malignant, with significant implications for reproductive health and overall survival 1.Diagnosis
Imaging: Transvaginal ultrasound and CT scans are essential for initial detection and staging 1.
Tumor Markers: CA-125 levels are often elevated in epithelial ovarian cancers but lack specificity; used in conjunction with imaging 1.
Biopsy: Definitive diagnosis requires histopathological examination of tumor tissue obtained via surgery 1.
Grading: Histological grading (1-3) based on tumor cell differentiation; higher grades indicate poorer prognosis 1.Management
Surgery: Primary treatment typically involves optimal cytoreductive surgery aiming for no residual disease 1.
Chemotherapy: First-line treatment often includes platinum-based regimens (e.g., carboplatin, cisplatin) combined with taxanes (e.g., paclitaxel) 1.
Immunotherapy: Emerging role for immunotherapy targeting tumor-associated antigens like HER-2/neu and CEA, particularly in HLA-A2.1 positive patients 1.Special Populations
Pregnancy: Management strategies vary; often requires multidisciplinary approach balancing maternal and fetal health 1.
Pediatrics: Limited data; treatment often adapted from adult protocols with close monitoring 1.
Elderly: Consideration of comorbidities; treatment tailored to maintain quality of life while addressing cancer 1.
Comorbidities: Presence of other diseases influences treatment selection and intensity; individualized care plans recommended 1.Key Recommendations
Utilize transvaginal ultrasound and CA-125 levels for initial screening and monitoring of epithelial ovarian tumors (Evidence: Moderate) 1.
Employ optimal cytoreductive surgery followed by platinum-based chemotherapy as first-line treatment (Evidence: Strong) 1.
Consider immunotherapy targeting specific tumor-associated antigens in HLA-A2.1 positive patients as an adjunctive therapy (Evidence: Weak) 1.References
1 Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E et al.. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Human immunology 1998. link00255-3)